Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Taprenepag (CP-544326) (CP-544326) is a potent and selective prostaglandin E2 receptor agonist (EC50 = 2.8 nM). Taprenepag has been used in trials studying the treatment of Ocular Hypertension and Glaucoma, Open-Angle.
説明 | Taprenepag (CP-544326) (CP-544326) is a potent and selective prostaglandin E2 receptor agonist (EC50 = 2.8 nM). Taprenepag has been used in trials studying the treatment of Ocular Hypertension and Glaucoma, Open-Angle. |
ターゲット&IC50 | Prostaglandin E2:2.8 nM(EC50) |
別名 | CP-544326 |
分子量 | 478.52 |
分子式 | C24H22N4O5S |
CAS No. | 752187-80-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (114.94 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Taprenepag 752187-80-7 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor pressure inhibit cells intraocular Inhibitor levels cAMP CP 544326 HEK293 CP544326 CP-544326 inhibitor